KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Average (2016 - 2025)

Historic Equity Average for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to $1.1 billion.

  • Supernus Pharmaceuticals' Equity Average rose 758.23% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 758.23%. This contributed to the annual value of $978.6 million for FY2024, which is 827.17% up from last year.
  • Supernus Pharmaceuticals' Equity Average amounted to $1.1 billion in Q3 2025, which was up 758.23% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Equity Average registered a high of $1.1 billion during Q3 2025, and its lowest value of $749.7 million during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $916.0 million (2023), whereas its average is $903.3 million.
  • Its Equity Average has fluctuated over the past 5 years, first soared by 2403.11% in 2021, then surged by 290.98% in 2024.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Equity Average stood at $813.2 million in 2021, then rose by 6.93% to $869.5 million in 2022, then grew by 5.45% to $916.9 million in 2023, then rose by 11.41% to $1.0 billion in 2024, then grew by 3.46% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.0 billion for Q2 2025, and $1.0 billion during Q1 2025.